VTYX beat EPS expectations by 21.05%
May 08, 2025, 10:37 PM
0.00%
What does VTYX do
Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.
Ventyx Biosciences (VTYX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ventyx Biosciences's actual EPS was -$0.39, beating the estimate of -$0.49 per share, resulting in a 21.05% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.